Loading clinical trials...

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer

NCT04381832•Arcus Biosciences, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Male participants; age ≥ 18 years
•Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with castrate levels of testosterone (≤1.7 nanomoles per liter \[nmol/L\] or 50 nanograms per deciliter \[ng/dL\])
•Measurable or non-measurable disease as per radiographic evaluation
•Participants with measurable disease may require a fresh tumor biopsy at study entry
•Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1
•Life expectancy of at least 3 months
•Adequate hematologic and end-organ function
•Human immunodeficiency virus (HIV), Hepatitis B, and C test results negative prior to first study treatment
•Disease progression after prior treatment with abiraterone
•Disease progression after prior androgen synthesis inhibitor therapy
+1 more criteria

Exclusion Criteria

•Prior treatment with immune checkpoint blockade therapy
•Prior anticancer treatment including approved agents, systemic radiotherapy, or investigational therapy, within 2-4 weeks prior first study treatment
•Corrected QT interval (QTc) ≥480 msec using Fredericia's QT correction formula (based on an average of triplicate recordings)
•Prior allogeneic stem cell or solid organ transplantation
•Prior treatment with drugs that stimulate the immune system within 4 weeks prior to first study treatment
•Prior treatment with drugs that suppress the immune system within 2 weeks prior to first study treatment
•Received a live, attenuated vaccine within 4 weeks prior to first study treatment, or may need to receive a vaccine during study treatment
•Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid - CSF (leptomeningeal disease)
•Prior pulmonary fibrosis, pneumonia, or pneumonitis
•Cancer other than prostate within 2 years prior to study entry, except for some cancers with a low risk of spreading like non-melanoma skin
+18 more criteria

Locations (19)

The Oncology Institute of Hope & Innovation

Cerritos, California, United States

The University of California, Los Angeles

Encino, California, United States

The University of California, Irvine Medical Center

Orange, California, United States

Florida Cancer Specialists South

Sarasota, Florida, United States

Florida Cancer Specialists North

St. Petersburg, Florida, United States

Florida Cancer Specialists Panhandle

Tallahassee, Florida, United States

Florida Cancer Specialists East

West Palm Beach, Florida, United States

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

Affinity Health Hope & Healing Cancer Services

Hinsdale, Illinois, United States

Johns Hopkins University

Baltimore, Maryland, United States

Key Dates

Start Date

July 7, 2020

Primary Completion Date

August 30, 2024

Completion Date

August 30, 2024

Last Updated

July 22, 2025

Enrollment

173

ACTUAL participants

Conditions

Prostatic Neoplasms, Castration-ResistantAndrogen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic NeoplasmsProstatic Cancer, Castration-Resistant

Interventions

Etrumadenant

DRUG

Zimberelimab

DRUG

Quemliclustat

DRUG

Enzalutamide

DRUG

Docetaxel

DRUG

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946

Prostatic Neoplasms, Castration-Resistant

View study

RECRUITINGPHASE1/PHASE2

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604

Prostatic Neoplasms, Castration-Resistant

View study

RECRUITINGPHASE1

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Inclusion Criteria

Exclusion Criteria

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer